- Yes-Associated Protein Expression Is Correlated to the Differentiation of Prostate Adenocarcinoma
-
Myung-Giun Noh, Sung Sun Kim, Eu Chang Hwang, Dong Deuk Kwon, Chan Choi
-
J Pathol Transl Med. 2017;51(4):365-373. Published online June 9, 2017
-
DOI: https://doi.org/10.4132/jptm.2017.05.04
-
-
6,061
View
-
181
Download
-
6
Citations
-
Abstract
PDF
- Background
Yes-associated protein (YAP) in the Hippo signaling pathway is a growth control pathway that regulates cell proliferation and stem cell functions. Abnormal regulation of YAP was reported in human cancers including liver, lung, breast, skin, colon, and ovarian cancer. However, the function of YAP is not known in prostate adenocarcinoma. The purpose of this study was to investigate the role of YAP in tumorigenesis, differentiation, and prognosis of prostate adenocarcinoma.
Methods The nuclear and cytoplasmic expression of YAP was examined in 188 cases of prostate adenocarcinoma using immunohistochemistry. YAP expression levels were evaluated in the nucleus and cytoplasm of the prostate adenocarcinoma and the adjacent normal prostate tissue. The presence of immunopositive tumor cells was evaluated and interpreted in comparison with the patients’ clinicopathologic data.
Results YAP expression levels were not significantly different between normal epithelial cells and prostate adenocarcinoma. However, YAP expression level was significantly higher in carcinomas with a high Gleason grades (8–10) than in carcinomas with a low Gleason grades (6–7) (p < .01). There was no statistical correlation between YAP expression and stage, age, prostate-specific antigen level, and tumor volume. Biochemical recurrence (BCR)–free survival was significantly lower in patients with high YAP expressing cancers (p = .02). However high YAP expression was not an independent prognostic factor for BCR in the Cox proportional hazards model.
Conclusions The results suggested that YAP is not associated with prostate adenocarcinoma development, but it may be associated with the differentiation of the adenocarcinoma. YAP was not associated with BCR.
-
Citations
Citations to this article as recorded by 
- NEK1-Mediated Phosphorylation of YAP1 Is Key to Prostate Cancer Progression
Ishita Ghosh, Md Imtiaz Khalil, Rusella Mirza, Judy King, Damilola Olatunde, Arrigo De Benedetti Biomedicines.2023; 11(3): 734. CrossRef - Epigenetic Inheritance From Normal Origin Cells Can Determine the Aggressive Biology of Tumor-Initiating Cells and Tumor Heterogeneity
Jiliang Feng, Dawei Zhao, Fudong Lv, Zhongyu Yuan Cancer Control.2022; 29: 107327482210781. CrossRef - A Yes-Associated Protein (YAP) and Insulin-Like Growth Factor 1 Receptor (IGF-1R) Signaling Loop Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma
Mai-Huong T. Ngo, Sue-Wei Peng, Yung-Che Kuo, Chun-Yen Lin, Ming-Heng Wu, Chia-Hsien Chuang, Cheng-Xiang Kao, Han-Yin Jeng, Gee-Way Lin, Thai-Yen Ling, Te-Sheng Chang, Yen-Hua Huang Cancers.2021; 13(15): 3812. CrossRef - Evidence for discrete modes of YAP1 signaling via mRNA splice isoforms in development and diseases
Jan Vrbský, Vladimir Vinarský, Ana Rubina Perestrelo, Jorge Oliver De La Cruz, Fabiana Martino, Antonio Pompeiano, Valerio Izzi, Ota Hlinomaz, Vladimir Rotrekl, Marius Sudol, Stefania Pagliari, Giancarlo Forte Genomics.2021; 113(3): 1349. CrossRef - Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers
Andreas Marx, Aljoscha Schumann, Doris Höflmayer, Elena Bady, Claudia Hube-Magg, Katharina Möller, Maria Christina Tsourlakis, Stefan Steurer, Franziska Büscheck, Till Eichenauer, Till S. Clauditz, Markus Graefen, Ronald Simon, Guido Sauter, Jakob R. Izbi Scientific Reports.2020;[Epub] CrossRef - NEK1 Phosphorylation of YAP Promotes Its Stabilization and Transcriptional Output
Md Imtiaz Khalil, Ishita Ghosh, Vibha Singh, Jing Chen, Haining Zhu, Arrigo De Benedetti Cancers.2020; 12(12): 3666. CrossRef
|